Author Index to Volume 35

Abbondanza D. See Myers JE
Abramovitch Y. See Levkovitz H
Achiron A, Noy S, Pras E, Lereya J, Hermesh H, Loar N. T-cell subsets in acute psychotic schizophrenic patients, 27
Akil H. See López JF
Aldanmaz F. See Özdemir MA
Ambrosini P. See Waterman GS
Ameli R. See Grillon C
Amend D. See Bell IR
Ancoli-Israel S. See Espiritu RC
Andreatini R, Sartori VA, Leite JR, Oliveira ASB. Panic attacks in a multiple sclerosis patient, 133
Andrews MW. See Rosenblum LA
Aniss AM. See Sachdev P
Arendt J. Clinical perspectives for melatonin and its agonists, 1-ed
Arpaia JP. See Globus GG
Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Brain 5-HT_{1A}, 5-HT_{1D}, and 5-HT_2 receptors in suicide victims, 457
Asarnow RF. See Strandburg RJ
Avrameas S. See Lévy-Soussan P
Azorin J-M. See Mazzola-Pomietto P

Baer L. See Savage CR
Bailey P. See Duval F
Bailly D, Servant D, Dewailly D, Beuscart R, Racadot A, Fossati P, Parquet P-J. Corticotropin releasing factor stimulation test in obsessive compulsive disorder, 143
Ball WA. See Ross RJ
Banich MT. See Stolar N
Barbouche R. See Lévy-Soussan P
Barch D. See Stolar N
Bar-Hamburger R. See Shufman EN
Barocka A. See Ebert D
Baron M. Novel strategies in molecular genetics of mental illness, 757-ed
Barsano CP, Garces J, Iqbal Z. Metabolic implications of low-dose triiodothyronine administration in rats: relevance to the adjunctive use of triiodothyronine in the treatment of depression, 814
Bartfai A. See Mårtensson B
Barthelemy C. See Hérault J
Bartzokis G, Sultzer D, Mintz J, Holt LE, Marx P, Phelan CK, Marder SR. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI, 480
Bassoff T. See Rosenblum LA
Baumgartner A. See Campos-Barros A
Beersma DGM. See Meesters Y
Bell IR. Somatization disorder: health care costs in the decade of the brain, 81-ed
Bell IR, Schwartz GE, Amend D, Peterson JM, Stini WA. Sensitization to early life stress and response to chemical odors in older adults, 857
Benkelfat C. See Roy BF
Berenbaum H. See Stolar N
Berger M. See Gann H
Berman N. See Swann AC
Bernstein S. See Pigott TA
Berry RB. See Reist C
Bessler H. See Weizman R
Beuscart R. See Bailly D
Biederman J. See Faraone SV
Birmaher B. See Waterman GS
Bissette G. See Lesem MD
Black B. See Brown TM
Black R. See Vaccarino FJ
Bossuyt A. See D'haenen HA
Bouhouys AL. See Meesters Y
Bowden CL. See Swann AC
Bräunig P. See Rao ML
Breslin N. See Roy BF
Brown D. See Kálmán J
Brown ES, Dilsaver SC, Shoaib AM, Swann AC. Depressive mania: response of residual depression to bupropion, 493
Brown RP. See McBride PA
Brown TM, Black B, Uhde TW. The sleep architecture of social phobia, 420
Brown WS. See Strandburg RJ
Brunberg JA. See DeQuardo JR
Bucci P. See Galderisi S
Buchler M. See Hérault J
Buhari A. See Kupfer DJ
Bunney WE Jr. See Reist C
Burke MA, McEvoy JP, Ritchie JC. A pilot study of a structured interview addressing sexual function in men with schizophrenia, 32

Caffarra P. See Coiro V
Caffarri G. See Coiro V
Calabrese JR. See Woyshville MJ
Caligiuri M, Lohr JB. A disturbance in the control of muscle force in neuroleptic-naive schizophrenic patients, 104
Callaway E. Toward better administration: treating malignant administrosis with leap-frog feedback, 827-ed
Callaway E, Casper R, Friedhoff A *Venus and Adonis*: an early account of sexual harassment,

Abbreviations:
ed: editorial
corr: correspondence

© 1994 Society of Biological Psychiatry

0006-3223/94/$07.00

294-ed (response)
Campos-Barros A, Baumgartner A. Effects of chronic desipramine treatment on thyroid hormone concentrations in rat brain: dependency on drug overdose and brain area, 214
Caplan R, Guthrie D. Blink rate in childhood schizophrenia spectrum disorder, 228
Casper R. See Callaway E
Chae Y-l. See Petty F
Chakraborty SP. See Khanna R
Chalmers DT. See López JF
Charney DS. See Salomon RM
Chatterjee S. See Haque Nizamie S
Chen C-C. See Reist C
Cherpi C. See Hérault J
Chhoeu A. See Reist C
Chiodera P. See Coiro V
Chuang D-M. See Margolis RL
Clark CR. See McFarlane AC
Claus D. See Rechlin T
Cohen A. See Weizman A
Cohen L. See Hollander E
Coiro V, Volpi R, Marchesi C, De Ferri A, d'Amato L, Caffarri G, Davolio M, Rossi E, Caffarra P, Chiodera P. Lack of seasonal variation in abnormal TSH secretion in patients with seasonal affective disorder, 36
Comazzi M. See Vita A
Cook IA. See Dunkin JJ
Cooper TB.
See Myers JE
See Sackeim HA
Coplan JD. See Rosenblum LA
Costa DC. See Ring HA
Cosyns P. See Maes M
Crocq M-A. See Duval F
Csernansky JG. See Zipursky RB

Dahl RE. See Waterman GS
d'Amato L. See Coiro V
Damodaran SS. See Khanna R
Daniel WF, Yeo RA. Accident proneness and handedness, 499-corr
Danielczyk W. See Fischer P
Dauphin MM. See Roy BF
Davé M. Clozapine-related tardive dyskinesia, 886
Davidson M. See Kahn RS
Davis KL. See Kahn RS
Davis M. See Grillon C
Davolio M. See Coiro V
DeCaria C. See Hollander E
De Ferri A. See Coiro V
de Leon J, Verghese C, Tracy JI, Josiassen RC, Simpson GM. Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature, 408
Delgado PL. See Salomon RM
DeLisi LE. See Hoff AL
DeMent S. See Zipursky RB
DeMeo M. See McBride PA
DeMet E. See Piletz JE
DeQuardo JR, Tandon R, Goldman R, Meador-Woodruff JH, McGrath-Giroux M, Brunberg JA, Kim L. Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia, 517
Devanand DP.
See Krueger RB
See Sackeim HA
Dewailly D. See Bailly D
Dey I. See Kálmán J
D'haenen HA, Bossuyt A. Dopamine D_2 receptors in depression measured with single photon emission computed tomography, 128
D'Hondt P. See Maes M
Dieci M. See Vita A
Dierks T. See Strik WK
Dilsaver SC. See Brown ES
Dinges DF. See Ross RJ
Djaldetti M. See Weizman R
Dorfman D. See Schroeder MM
Dubovsky SL. Why don't we hear more about the calcium antagonists? An industry—academia interaction, 149-ed
Duffy FH. See Savage CR
Duncan WC Jr, Schull J. The interaction of thyroid state, MAOI drug treatment, and light on the level and circadian pattern of wheel-running in rats, 324
Dündar S. See Özdemir MA
Dunkin JJ, Leuchter AF, Newton TF, Cook IA. Reduced EEG coherence in dementia: state or trait marker?, 870
Duval F, Mokrani M-C, Crocq M-A, Bailey P, Macher J-P. Influence of thyroid hormones on morning and evening TSH response to TRH in major depression, 926

Ebert D, Feistel H, Kaschka W, Barocka A, Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation—preliminary results, 880
Egan MF. See Elkashef AM
Ehlers CL. See Kupfer DJ
Eldar S. See Toren P
Elin RJ. See Rosenstein DL
Elkashef AM, Egan MF, Frank JA, Hyde TM, Lewis BK, Wyatt RJ. Basal ganglia iron in tardive dyskinesia: an MRI study, 16
Ell PJ. See Ring HA
Ellinger B. See Fischer P
Eriksson A. See Arranz B
Esel E. See Özdemir MA
Espiritu RC, Kripke DF, Ancoli-Israel S, Mowen MA, Mason WJ, Fell RL, Klauber MR, Kaplan OJ. Low illumination experienced by San Diego adults: association with atypical depressive symptoms, 403

Faraone SV. See Seidman LJ
Faraone SV, Biederman J, Milberger S. An exploratory study of ADHD among second-degree relatives of ADHD children, 398
Farkas T. See Kálmán J
Faull KF. See Ringo DL
Faustman WO. See Ringo DL
Feistel H. See Ebert D
Fell RL. See Espiritu RC
Fernstrom JD. See Weltzin TE
Fischer P, Götz ME, Ellinger B, Streifler M, Riederer P, Danielczyk W. Platelet monoamine oxidase B activity and vitamin B_{12} in dementia, 772
Fluhr H. See Weizman A
Ford JM, White P, Lim KO, Pfefferbaum A. Schizophrenics have fewer and smaller P300s: a single-trial analysis, 96
Fossati P. See Bailly D
Frank E. See Kupfer DJ
Frank JA. See Elkashef AM
Franzek E. See Strik WK
Friedhoff A. See Callaway E
Friedman EH. The neurobiology of posttraumatic stress disorder (PTSD), 500-corr
Friedman S. See Rosenblum LA
Fukuda R. See Sasaki T

Galderisi S, Maj M, Mucci A, Bucci P, Kemali D. QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients, 367
Galinowski A. See Lévy-Soussan P
Gandacu D. See Shufman EN
Ganguli R. See Silver MA
Gann H, Riemann D, Hohagen F, Müller WE, Berger M. The influence of carbamazepine on sleep-EEG and the clonidine test in healthy subjects: results of a preliminary study, 893
Garbarini M. See Vita A
Garces J. See Barsano CP
Geisler S. See Szymanski S
George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI, 775
Gilbertson MW, Yao JK, van Kammen DP. Memory and plasma HVA changes in schizophrenia: are they episode markers?, 203
Gillin JC, Pulvirenti L, Withers N, Golshan S, Koob G. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report, 843
Ginath Y. See Shufman EN
Giobbio GM. See Vita A
Globus GG, Arpaia JP. Psychiatry and the new dynamics, 352
Glovinsky D. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients, 429-corr (response)
Goddard A. See Grillon C
Goldberg JF, Harrow M. Kindling in bipolar disorders: a longitudinal follow-up, 70
Goldman R. See DeQuardo JR
Goldstein JM. See Seidman LJ
Golshan S. See Gillin JC
Goossens F. See Maes M
Gorman JM. See Rosenblum LA
Götz ME. See Fischer P
Grady TA. See Pigott TA
Grillon C, Ameli R, Goddard A, Woods SW, Davis M. Baseline and fear-potentiated startle in panic disorder patients, 431
Grochocinski VJ. See Kupfer DJ
Gross G. See Rao ML
Gross-Isseroff R, Luca-Haimovici K, Sasson Y, Kindler S, Kotler M, Zohar J. Olfactory sensitivity in major depressive disorder and obsessive compulsive disorder, 798
Grover G. See Rosenstein DL
Guidotti A. See George MS
Gur RC. See Gur RE
Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC. Cerebral blood flow in schizophrenia: effects of memory processing on regional activation, 3
Guthrie D.
  See Caplan R
  See Strandburg RJ
Gwirtsman HE. See Piletz JE

Halaris A.
  See Piletz JE
  See Rao ML
Hallén B. See Mårtensson B
Han JH. See Rapaport MH
Hanada K. See Poland RE
Handelsman L. See Schroeder MM
Haque Nizamie S, Chatterjee S, Kumar BV, Sharma LN. Transient release reflexes in affective psychoses, 217
Harrison K. See Russ MJ
Harrow M. See Goldberg JF
Hellström C. See Mårtensson B
Hérault J, Petit E, Buchler M, Martineau J, Cherpi C, Perrot A, Sauvage D, Barthelemy C, Muh JP, Lelord G. Lack of association between three genetic markers of brain growth factors and infantile autism, 281
Hermesh H. See Achiron A
Higa J. See Strandburg RJ
Hill JL.
  See Pigott TA
  See Roy BF
Hoff AL, Neal C, Kushner M, DeLisi LE. Gender differences in corpus callosum size in first-episode schizophrenics, 913
Hohagen F. See Gann H
Hollander E, DeCaria C, Stein D, Simeon D, Cohen L, Hwang M, Islam M. Behavioral response to m-CPP, 426-corr
Holt LE. See Bartzokis G
Horie T. See Murata T
Hornykeiwicz O. See Young LT
Hosseini JM. See Rosenstein DL
Huber G. See Rao ML
Hufford C. See Weiss RD
Hull JW. See Russ MJ
Hwang M. See Hollander E
Hyde TM. See Elkashef AM

Inbar D. See Weizman A
Inglot AD, Leszek J, Piasecki E, Sypula A. Interferon responses in schizophrenia and major depressive disorders, 464
Invernizzi G. See Vita A
Iqbal Z. See Barsano CP
Isaki K. See Murata T
Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis, 84
Islam M. See Hollander E

Jackson JG. See Lauterbach EC
Jacobson J. See Schroeder MM
Jaggi JL. See Gur RE
Janka Z. See Kálmán J
Jansen JHC. See Meesters Y
Jeanningros R. See Mazzola-Pomietto P
Jenike MA. See Savage CR
Jimerson DC. See Lesem MD
Joó F. See Kálmán J
Jordan S. See Petty F
Josiassen RC. See de Leon J
Junthé T. See Mårtensson B

Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, *m*-chlorophenylpiperazine, 909
Kakuma T. See Russ MJ
Kálmán J, Dey I, Varga Ilona S, Matkovics B, Brown D, Janka Z, Farkas T, Joó F. Platelet membrane fluidity and plasma malondialdehyde levels in Alzheimer's demented patients with and without family history of dementia, 190
Kane J. See Szymanski S
Kaplan OJ. See Espiritu RC
Kaschka W. See Ebert D
Kawate T. See Sasaki T
Kaye WH.

See Lesem MD
See Weltzin TE
Kazamatsuri H. See Sasaki T
Kehat R. See Weizman A
Keilp J. See McBride PA
Kelly TM. See Roy BF
Kemali D. See Galderisi S
Kennedy SH. See Vaccarino FJ
Khanna R, Damodaran SS, Chakraborty SP. Overflow movements may predict neuroleptic-induced dystonia, 491
Kim L. See DeQuardo JR
Kim YS. See Rapaport MH
Kindler S. See Gross-Isseroff R
Kirch DG. See Rapaport MH
Kirsh AD. See Lauterbach EC
Kish SJ. See Young LT
Klauber MR. See Espiritu RC
Koek RJ, Lloyd R, Satlin A. Does oxytocin release correlate with ECT's efficacy?, 963-corr
Koob G. See Gillin JC
Koshino Y. See Murata T
Koslow SH. See Swann AC
Kotler M. See Gross-Isseroff R
Kramer G. See Petty F
Kremen WS. See Seidman LJ
Kribbs NB. See Ross RJ
Kripke DF. See Espiritu RC
Kritz A. See Nachshoni T
Krueger RB, Devanand DP, Prudic J, Sackeim HA. Some comments on the question 'does ECT permanently alter seizure threshold?', 427-corr (response)
Kumar BV. See Haque Nizamie S
Kunugi H. See Sasaki T
Kupfer DJ, Ehlers CL, Frank E, Grochocinski VJ, McEachran AB, Buhari A. Persistent effects of antidepressants: EEG sleep studies in depressed patients during maintenance treatment, 781
Kurumaji A. See Ishimaru M
Kushner M. See Hoff AL

Laor N. See Weizman R
Lauterbach EC, Price ST, Spears TE, Jackson JG, Kirsh AD. Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm, 488
Lauterbach EC, Spears TE, Prewett MJ, Price ST, Jackson JG, Kirsh AD. Neuropsychiatric disorders, myoclonus, and dystonia in calcification of basal ganglia pathways, 345
Leite JR. See Andreatini R
Lelord G. See Hérault J
Lereya J. See Achiron A
Lesem MD, Kaye WH, Bissette G, Jimerson DC, Nemeroff CB. Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa, 48
Leszek J. See Inglot AD
Leuchter AF. See Dunkin JJ
Levin Y. See Nachshoni T
Levkovitz H, Abramovitch Y, Nitzan A. Leukocytosis related to the therapeutic dosage of sulpiride, 963-corr
Levy A. See Nachshoni T
Lévy-Soussan P, Barbouche R, Poirier M-F, Galinowski A, Lôo H, Avrameas S. A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics, 135
Lewis BK. See Elkashef AM
Lieberman J. See Szymanski S
Lim KO.
See Ford JM
See Zipursky RB
Lindley SE. See Ringo DL
Linsner JP. See Pollack CP
Lloyd R. See Koek RJ
Loar N. See Achiron A
Loebel A. See Szymanski S
Lohr JB. See Caligiuri M
Lôo H. See Lévy-Soussan P
López JF, Chalmers DT, Vásquez DM, Watson SJ, Akil H. Serotonin transporter mRNA in rat brain is regulated by classical antidepressants, 287
Luca-Haimovici K. See Gross-Isseroff R

Maas JW. See Swann AC
Macher J-P. See Duval F
MacMillan H, Steiner M. Atrial natriuretic factor: does it have a role in psychiatry?, 272
Maes M. See Meltzer HY
Maes M, Goossens F, Scharpé S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression, 545
Magor A. See Toren P
Maj M.
See Galderisi S
See Monteleone P
Malhotra S. See Santosh PJ
Mamczarz J. See Popik P
Mandel M. See Toren P
Manji H. See Rapaport MH
Mann JJ.
See McBride PA
See Myers JE
Many A. See Toren P
Marchesi C. See Coiro V
Marcusson J. See Arranz B
Marder SR. See Bartzokis G
Margolis RL, Chuang D-M, Post RM. Programmed cell death: implications for neuropsychiatric disorders, 946
Marler M. See Rao ML
Marsh JT. See Strandburg RJ
Marsh L. See Zipursky RB
Mårtensson B, Bartfai A, Hallén B, Hellström C, Junthé T, Olander M. A comparison of propofol and methohexital as anesthetic agents for ECT: effects on seizure duration, therapeutic outcome, and memory, 179
Martineau J. See Hérault J
Marx P. See Bartzokis G
Masiar S. See Szymanski S
Mason WJ. See Espiritu RC
Matkovics B. See Kálmán J
Maurer K. See Strik WK
Mayerhoff D. See Szymanski S
Mazure CM. See Salomon RM
Mazzola-Pomietto P, Azorin J-M, Tramoni V, Jeanningros R. Relation between lymphocyte β-adrenergic responsivity and the severity of depressive disorders, 920
McAllister CG. See Rapaport MH
McBride PA, Brown RP, DeMeo M, Keilp J, Mieczkowski T, Mann JJ. The relationship of platelet 5-HT_2 receptor indices to major depressive disorder, personality traits, and suicidal behavior, 295
McConaha C. See Weltzin TE
McEachran AB. See Kupfer DJ
McEvoy JP. See Burke MA
McFarlane AC, Clark CR. The

neurobiology of posttraumatic stress disorder (PTSD), 500-corr (response)
McGrath-Giroux M. See DeQuardo JR
Meador-Woodruff JH. See DeQuardo JR
Meesters Y, Jansen JHC, Beersma DGM, Bouhouys AL, van den Hoofdakker RH. An attempt to prevent winter depression by light exposure at the end of September, 284
Mehra YN. See Santosh PJ
Mellerup E. See Arranz B
Meltzer HY. See Maes M
Meltzer HY, Maes M. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects, 316
Mendelson JH. See Weiss RD
Mendia P. See Salomon RM
Mester R.
See Toren P
See Weizman A
Mieczkowski T.
See McBride PA
See Myers JE
Miettinen Professor TA. See Strandberg TE
Mikalauskas K. See George MS
Milberger S. See Faraone SV
Mintz J. See Bartzokis G
Mokrani M-C. See Duval F
Monteleone P, Orazzo C, Natale M, Maj M. Lack of effect of short-term fluoxetine administration on nighttime plasma melatonin levels in healthy subjects, 139
Morganti C. See Vita A
Moriarty J. See Ring HA
Morrison AR. See Ross RJ
Mowen MA. See Espiritu RC
Mozes T. See Toren P
Mucci A. See Galderisi S
Muh JP. See Hérault J
Müller WE. See Gann H
Mulvaney FD. See Ross RJ
Murata I. See Murata T
Murata T, Koshino Y, Omori M, Murata I, Nishio M, Horie T, Isaki K. Quantitative EEG study on premature aging in adult Down's syndrome, 422
Murphy DL. See Pigott TA
Murphy GM. See Zipursky RB
Myers JE, Mieczkowski T, Perel J, Abbondanza D, Cooper TB, Mann JJ. Abnormal behavioral responses to fenfluramine in patients with affective and personality disorders: correlation with increased serotonergic responsivity, 112

Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M. A double-blind trial of carbamazepine in negative symptom schizophrenia, 22
Nanko S. See Sasaki T
Natale M. See Monteleone P
Neal C. See Hoff AL
Nelson B. See Waterman GS
Nelson DL. See Rapaport MH
Nemeroff CB. See Lesem MD
Neumann M. See Nachshoni T
Newton TF. See Dunkin JJ
Nimgaonkar VL. See Silver MA
Nishio M. See Murata T
Nitzan A. See Levkovitz H
Notti I. See Weizman R
Novacenko H. See Waterman GS
Noy S. See Achiron A

Olander M. See Mårtensson B
Oliveira ASB. See Andreatini R
Omori M. See Murata T
Orazzo C. See Monteleone P
Özdemir MA, Sofuoğlu S, Tanrikulu G, Aldanmaz F, Esel E, Dündar S. Lithium-induced hematologic changes in patients with bipolar affective disorder, 210

Pan B. See George MS
Parquet P-J. See Bailly D
Partinen M. See Strandberg TE
Paul SM. See Rapaport MH
Perel J. See Myers JE
Perlick D. See Pollack CP
Perrot A. See Hérault J
Peterson JM. See Bell IR
Petit E. See Hérault J
Petty F, Chae Y-l, Kramer G, Jordan S, Wilson L. Learned helplessness sensitizes hippocampal norepinephrine to mild restress, 903
Pfefferbaum A.
See Ford JM
See Zipursky RB
Pfohl B. See Tómasson K
Phelan CK. See Bartzokis G
Piasecki E. See Inglot AD
Pickar D. See Rapaport MH
Pierce PF. See Roy BF
Pigott TA, Murphy DL, Hill JL, Grady TA, Bernstein S. Behavioral response to m-CPP, 426-corr (response)
Pihl S. See Strandberg TE
Piletz JE, DeMet E, Gwirtsman HE, Halaris A. Disruption of circadian MHPG rhythmicity in major depression, 830
Pirner A. See Ebert D
Pitts AF. See Samuelson SD
Plenge P. See Arranz B
Podliszewski E. See Weizman R
Poirier M-F. See Lévy-Soussan P
Poland RE, Hanada K. Dissociation between plasma bioactive and immunoactive ACTH concentrations in depressed patients, 309
Pollack CP, Perlick D, Linsner JP. Sleep and motor activity of community elderly who frequently use bedtime medications, 73
Pollack S. See Szymanski S
Popik P, Mamczarz J, Vetulani J. The effect of electroconvulsive shock and nifedipine on spatial learning and memory in rats, 864
Porat S. See Shufman EN
Post RM.
See George MS
See Margolis RL
Pras E. See Achiron A
Prewett MJ. See Lauterbach EC
Price ST. See Lauterbach EC
Prudic J. See Krueger RB, 427
Puig-Antich J. See Waterman GS
Pulvirenti L. See Gillin JC

Rabinovich H. See Waterman GS
Racadot A. See Bailly D
Raghunathan M. See Santosh PJ
Ragland JD. See Gur RE
Räikkönen K. See Strandberg TE
Ralevski E. See Vaccarino FJ
Rao ML, Gross G, Strebel B, Halaris A, Huber G, Bräunig P, Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia, 151
Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, Kirch DG, Paul SM. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients,

767
Rapaport MH, Schmidt ME, Risinger R, Manji H. The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements, 761
Rechavi G. See Toren P
Rechlin T, Claus D, Weis M. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine, 888
Rehavi M. See Weizman A
Reist C, Chen C-C, Chhoeu A, Berry RB, Bunney WE Jr. Effects of sleep on the antidepressant response to sleep deprivation, 794
Riederer P. See Fischer P
Riemann D. See Gann H
Rinaldi P. See Schroeder MM
Ring HA, Trimble MR, Costa DC, Moriarty J, Verhoeff NPLG, Ell PJ. Striatal dopamine receptor binding in epileptic psychoses, 375
Ringo DL, Lindley SE, Faull KF, Faustman WO. Cholesterol and serotonin: seeking a possible link between blood cholesterol and CSF 5-HIAA, 957
Risinger R. See Rapaport MH
Ritchie JC. See Burke MA
Ritter W. See Schroeder MM
Rosenblum LA, Coplan JD, Friedman S, Bassoff T, Gorman JM, Andrews MW. Adverse early experiences affect noradrenergic and serotonergic functioning in adult primates, 221
Rosenstein DL, Elin RJ, Hosseini JM, Grover G, Rubinow DR. Magnesium measures across the menstrual cycle in premenstrual syndrome, 557
Ross RJ, Ball WA, Dinges DF, Kribbs NB, Morrison AR, Silver SM, Mulvaney FD. Rapid eye movement sleep disturbance in posttraumatic stress disorder, 195
Rossi E. See Coiro V
Roth SD. See Russ MJ
Roy BF, Benkelfat C, Hill JL, Pierce PF, Dauphin MM, Kelly TM, Sunderland T, Weinberger DR, Breslin N. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection, 335
Rubinow D. See George MS
Rubinow DR. See Rosenstein DL
Russ MJ, Roth SD, Kakuma T, Harrison K, Hull JW. Pain perception in self-injurious borderline patients: naloxone effects, 207
Ryan ND. See Waterman GS

Sachdev P. A rating scale for acute drug-induced akathisia: development, reliability, and validity, 263
Sachdev P, Aniss AM. Slowness of movement in melancholic depression, 253
Sackeim HA. See Krueger RB
Sackeim HA, Devanand DP, Cooper TB. Comment on 'Does Oxytocin Release Correlate with ECT's Efficacy?', 964-corr
Salomon RM, Mazure CM, Delgado PL, Mendia P, Charney DS. Serotonin function in aggression: the effect of acute plasma tryptophan depletion in aggressive patients, 570
Samuelson SD, Winokur G, Pitts AF. Elevated cerebrospinal fluid protein in men with unipolar or bipolar depression, 539
Santosh PJ, Malhotra S, Raghunathan M, Mehra YN. A study of P300 in melancholic depression—correlation with psychotic features, 474
Sartori VA. See Andreatini R
Sasaki T, Nanko S, Fukuda R, Kawate T, Kunugi H, Kazamatsuri H. Changes of immunological functions after acute exacerbation in schizophrenia, 173
Sasson Y. See Gross-Isseroff R
Satlin A. See Koek RJ
Sauvage D. See Hérault J
Savage CR, Weilburg JB, Duffy FH, Baer L, Shera DM, Jenike MA. Low-level sensory processing in obsessive-compulsive disorder: an evoked potential study, 247
Scharpé S. See Maes M
Schmidt ME. See Rapaport MH
Schroeder MM, Handelsman L, Torres L, Dorfman D, Rinaldi P, Jacobson J, Wiener J, Ritter W. Early and late cognitive event-related potentials mark stages of HIV-1 infection in the drug-user risk group, 54
Schull J. See Duncan WC Jr
Schwartz GE. See Bell IR
Scott AIF. Does oxytocin release correlate with ECT's efficacy?, 964-corr (response)
Secunda SK. See Swann AC
Seidman LJ, Yurgelun-Todd D, Kremen WS, Woods BT, Goldstein JM, Faraone SV, Tsuang MT. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia, 235
Servant D. See Bailly D
Sevy S. See Kahn RS
Shannak K. See Young LT
Sharma LN. See Haque Nizamie S
Shear PK. See Zipursky RB
Shedlack KJ, Soldato-Couture C, Swanson CL Jr. Rapidly progressive tardive dyskinesia in AIDS, 147-corr
Shera DM. See Savage CR
Shoaib AM. See Brown ES
Shtasel DL. See Gur RE
Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification, 935
Siever LJ. See Kahn RS
Silver MA, Yang ZW, Ganguli R, Nimgaonkar VL. An inhibitory effect of psychoactive drugs on a human neuroblastoma cell line, 824
Silver SM. See Ross RJ
Simeon D. See Hollander E
Simpson GM. See de Leon J
Sofuoğlu S. See Özdemir MA
Soldato-Couture C. See Shedlack KJ
Spears TE. See Lauterbach EC
Stein D. See Hollander E
Steiner M. See MacMillan H
Stini WA. See Bell IR
Stöber G. See Strik WK
Stokes PE. See Swann AC

Stolar N, Berenbaum H, Banich MT, Barch D. Neuropsychological correlates of alogia and affective flattening in schizophrenia, 164
Strandberg TE, Räikkönen K, Partinen M, Pihl S, Vanhanen H, Miettinen TA. Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men, 575
Strandburg RJ, Marsh JT, Brown WS, Asarnow RF, Higa J, Guthrie D. Continuous-processing related ERPS in schizophrenic and normal children, 525
Strebel B. See Rao ML
Streifler M. See Fischer P
Strik WK, Dierks T, Franzek E, Stöber G, Maurer K. P300 in schizophrenia: interactions between amplitudes and topography, 850
Sullivan EV. See Zipursky RB
Sultzer D. See Bartzokis G
Sunderland T. See Roy BF
Swann AC. See Brown ES
Swann AC, Stokes PE, Secunda SK, Maas JW, Bowden CL, Berman N, Koslow SH. Depressive mania versus agitated depression: biogenic amine and hypothalamic–pituitary–adrenocortical function, 803
Swanson CL Jr. See Shedlack KJ
Sypula A. See Inglot AD
Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, Kane J, Lieberman J. Clozapine response in treatment-refractory first-episode schizophrenia, 278

Tandon R. See DeQuardo JR
Tanrikulu G. See Özdemir MA
Terao T. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients, 429-corr
Tómasson K, Winokur G, Pfohl B. Some comments on the question 'does ECT permanently alter seizure threshold?', 427-corr
Toren A. See Toren P
Toren P, Toren A, Weizman A, Mozes T, Eldar S, Magor A, Mandel M, Rechavi G, Many A, Mester R. Tourette's disorder: is there an association with the antiphospholipid syndrome?, 495
Torres L. See Schroeder MM
Toru M. See Ishimaru M
Tracy JI. See de Leon J
Tramoni V. See Mazzola-Pomietto P
Trimble MR. See Ring HA
Tsuang MT. See Seidman LJ

Uhde TW. See Brown TM
Unis AS. [^{3}H]-SCH23390 and [^{3}H]-YM09151-2 binding sites in human fetal forebrain, 562

Vaccarino FJ, Kennedy SH, Ralevski E, Black R. The effects of growth hormone-releasing factor on food consumption in anorexia nervosa patients and normals, 446
van den Hoofdakker RH. See Meesters Y
Vanhanen H. See Strandberg TE
van Kammen DP. See Gilbertson MW
Varga Ilona S. See Kálmán J
Vásquez DM. See López JF
Verghese C. See de Leon J
Verhoeff NPLG. See Ring HA
Vetulani J. See Popik P
Vita A, Giobbio GM, Dieci M, Garbarini M, Morganti C, Comazzi M, Invernizzi G. Stability of cerebral ventricular size from the appearance of the first psychotic symptoms to the later diagnosis of schizophrenia, 960
Volpi R. See Coiro V

Warsh JJ. See Young LT
Waterman GS, Dahl RE, Birmaher B, Ambrosini P, Rabinovich H, Williamson D, Novacenko H, Nelson B, Puig-Antich J, Ryan ND. The 24-hour pattern of prolactin secretion in depressed and normal adolescents, 440
Watson SJ. See López JF
Weilburg JB. See Savage CR
Weinberger DR. See Roy BF
Weis M. See Rechlin T
Weiss RD, Hufford C, Mendelson JH. Serum prolactin levels and treatment outcome in cocaine dependence, 573
Weitz R. See Weizman A
Weizman A. See Toren P
Weizman A, Fluhr H, Weitz R, Kehat R, Inbar D, Cohen A, Mester R, Rehavi M. Platelet serotonin transporter in drug-naive migrainous children and adolescents, 452
Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment, 42
Weltzin TE, Fernstrom JD, McConaha C, Kaye WH. Acute tryptophan depletion in bulimia: effects on large neutral amino acids, 388
White P. See Ford JM
Wiener J. See Schroeder MM
Williamson D. See Waterman GS
Wilson L. See Petty F
Winokur G.
See Samuelson SD
See Tómasson K
Withers N. See Gillin JC
Witztum E. See Shufman EN
Woods BT. See Seidman LJ
Woods SW. See Grillon C
Wortis J.
Charles Shagass (in memoriam), 365
In memoriam: Williamina Elizabeth Armstrong Himwich, 291
Remembering Paul Hoch, 901-ed
Venus and Adonis: an early account of sexual harassment, 293-ed
Woyshville MJ, Calabrese JR. Quantification of occipital EEG changes in Alzheimer's disease utilizing a new metric: the fractal dimension, 381
Wyatt RJ. See Elkashef AM

Yang ZW. See Silver MA
Yao JK. See Gilbertson MW
Yatham LN. Buspirone induced prolactin release in mania, 553
Yeo RA. See Daniel WF, 499
Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder, 121
Yurgelun-Todd D. See Seidman LJ

Zipursky RB, Marsh L, Lim KO, DeMent S, Shear PK, Sullivan EV, Murphy GM, Csernansky JG, Pfefferbaum A. Volumetric MRI assessment of temporal lobe structures in schizophrenia, 501
Zohar J. See Gross-Isseroff R

Subject Index for Volume 35

Abnormal Involuntary Movements Scale (AIMS)
  tardive dyskinesia in AIDS and, 147-corr
Abstraction measures
  dorsolateral prefrontal lobe and, 235
Accident proneness
  handedness and, 499-corr
N-Acetyl-5-hydroxytryptamine
  melatonin and, 139
N-Acetyltransferase
  melatonin and, 139
Acoustic startle reflex
  in panic disorder, 431
Acquired immunodeficiency syndrome (AIDS)
  event-related potentials in HIV-1 infection and, 54
  rapidly progressive tardive dyskinesia in, 147-corr
Adolescents
  major depressive disorder in, 440
  migrainous, platelet serotonin transporter in, 452
  schizophrenia onset in, 517
α-Adrenergic receptors
  melatonin and, 139
β-Adrenergic receptors
  lymphocyte, depression and, 920
  melatonin and, 139
Adrenocorticotropic hormone (ACTH)
  clozapine and, 909
  in depression, 309
  in obsessive-compulsive disorder, 143
  prolyl endopeptidase and, 545
Adverse experiences
  affect functioning in adult primates, 221
A.E. Bennett Research Awards 1994
  guidelines and instructions for, 77
Affect
  pathological, thalamic infarct and, 488
Affective disorders
  adverse early experiences and, 221
  CSF neuroactive steroids in, 775
  fenfluramine in, 112
  multiple sclerosis and, 133
  somatization disorder and, 81-ed
Affective flattening
  in major depressive disorder, 464
  in schizophrenia, 164, 464
Affective psychoses
  transient release reflexes in, 217
Affective relapse
  kindling in bipolar disorders and, 70
Age
  brain iron in Alzheimer's disease and, 480
  cacosmia and, 857
  cytokine production in major depression and, 42
  obsessive-compulsive disorder and, 247
  P300 in melancholic depression and, 474
  prolyl endopeptidase and, 545
Aggressivity
  cholesterol lowering and, 575
  serotonin function and, 570
Agitation
  biogenic amines and, 803
  fenfluramine challenge test and, 112
  HPA function and, 803
  MHPG in major depression and, 830
AIDS dementia complex (ADC)
  event-related potentials in HIV-1 infection and, 54
Akathisia
  drug-induced, rating scale for, 263
Alcoholism
  in posttraumatic stress disorder, 195
  in somatization disorder, 81-ed
Allergies
  cacosmia and, 857
Alogia
  in schizophrenia, 164
Alzheimer's disease
  brain iron in, 480
  Down's syndrome and, 422
  EEG in, 870
  fractal dimension in, 381
  monoamine oxidase B in, 772

Abbreviations:
ed: editorial
corr: correspondence

© 1994 Society of Biological Psychiatry

0006-3223/94/$07.00

platelet membrane fluidity in, 190
programmed cell death in, 946
serum antibody in, 335
vitamin B_{12} in, 772
Amines
biogenic, in mixed affective states, 803
Amino acids
large neutral, tryptophan depletion in bulimia and, 388
Amitriptyline
serotonin transporter mRNA and, 287
Amnesia
basal ganglia calcification in, 345
ECT and nifedipine effects on, 864
Amotivation
thalamic infarct and, 488
[^{3}H] AMPA
glycine binding sites in schizophrenia and, 85
Amphetamine
lisuride and, 843
Analgesia
in self-injurious borderline patients, 207
Analgesics
minor, use of by elderly, 73
Androstenone
olfactory sensitivity to in major depressive disorder and obsessive-compulsive disorder, 798
Anergia
fenfluramine challenge test and, 112
thalamic infarct and, 488
Anesthetic agents
for ECT, 179
Anger
cholesterol lowering and, 575
Anhedonia
in psychostimulant withdrawal, 843
thalamic infarct and, 488
Anorexia nervosa
CSF TRH in, 48
growth hormone-releasing factor in, 446
Antibodies
anticardiolipin, in Tourette's disorder, 495
antinuclear, schizophrenia and, 135
serum, for somatostatin-14 and prodynorphin, 209-240, 335
Anticholinergics
overflow movements and, 491
Anticipatory anxiety
in panic disorder, 431
Anticonvulsants
negative symptoms in schizophrenia and, 22
Antidepressants
cytokine production in major depression and, 42
EEG sleep and, 781
in elderly, 73
olfactory sensitivity and, 798
serotonin transporter mRNA and, 287
thyroid state, light and, 324
tricyclic, see Tricyclic antidepressants
Antihistaminics
use of by elderly, 73
Antiphospholipid syndrome
Tourette's disorder and, 495
Antipsychotic drugs
for mixed states, 493
sexual function in schizophrenic men and, 32
Anxiety disorders
adverse early experiences and, 221
basal ganglia calcification and, 345
multiple sclerosis and, 133
Anxiety dreams
in posttraumatic stress disorder, 195
Anxiety response
in akathisia, 263
basal ganglia calcification and, 345
cacosmia and, 857
fenfluramine challenge test and, 112
in migraine, 452
in panic disorder, 431
in social phobia, 420
in somatization disorder, 81-ed
thalamic infarct and, 488
Apathy
interferon responses in schizophrenia and MDD and, 464
Apoptosis
in neuropsychiatric disorders, 946
Appetite surge
thalamic infarct and, 488
Arginine vasopressin
in major depression, 545
Asociality
interferon responses in schizophrenia and MDD and, 464
Atrial natriuretic factor (ANF)
in psychiatry, 272
Attention deficit hyperactivity disorder (ADHD)
among second-degree relatives, 398
Attention impairment
interferon responses in schizophrenia and MDD and, 464
Auditory evoked potentials
in HIV-1 infection, 54
in obsessive-compulsive disorder, 247
Autism
infantile, 281
programmed cell death in, 946
Autoantibodies
natural, in schizophrenia, 135
in Tourette's disorder, 495
Autoimmune response
in obsessive-compulsive disorder, 335
prolyl endopeptidase and, 545
in schizophrenia, 135
Autonomic nervous system (ANS)
clozapine and, 888
Autumn
seasonal affective disorder and, 36, 284
Avolition
interferon responses in schizophrenia and MDD and, 464

Ballistic movements
in melancholia, 253
Barnes Akathisia Rating Scale
reliability and validity of, 263
Basal ganglia
calcification of, 345
D_2 receptors in depression and, 128
iron, in tardive dyskinesia, 16
Baseline startle
in panic disorder, 431
Beck Depression Inventory
thalamic infarct and, 488
Bedtime medications
effect of on sleep and motor activity in elderly, 73
Behavioral response
to *m*CPP, 426-corr
Benzodiazepines
use of by elderly, 73
Binaural click stimulation
in obsessive-compulsive disorder, 247
Bipolar disorder
biogenic amines in, 803
brain monoamines in, 121
bupropion for, 493
calcium antagonists for, 149
CSF protein in, 539
HPA function in, 803
kindling in, 70
lithium-induced hematologic changes in, 210
transient release reflexes in, 217
triiodothyronine in, 814
Bizarre behavior
interferon responses in schizophrenia and MDD and, 464
Blepharospasm
thalamic infarct associated with, 488
Blindness
melatonin and, 1-ed
Blink rate
in childhood schizophrenia, 228
Blood
magnesium measures across menstrual cycle in PMS and, 557
Blood flow
cerebral, in schizophrenia, 3
Blood pressure
melatonin and, 1-ed
Borderline personality disorder (BPD)
self-injurious behavior in, 207
serotonin receptor function and, 295
Bradykinesia
slowness of movement and, 253
Brain
atrial natriuretic factor in, 272
HIV-1 infection of, 54
iron content in, 16, 480
Breast cysts
cacosmia and, 857
Brief Psychiatric Rating Scale
carbamazepine in schizophrenia and, 22
immunological function in schizophrenia and, 173
Briquet's syndrome
health care costs and, 81-ed
Bulimia nervosa
growth hormone-releasing factor in, 446
tryptophan depletion in, 388
Bupropion
for depressive mania, 493
thalamic infarct and, 489
Buspirone
for depression, 316
prolactin release in mania and, 553

Ca-calmodulin system
carbamazepine in schizophrenia and, 23
Cacosmia
in older adults, early life stress sensitization and, 857
Caenorhabditis elegans
programmed cell death and, 946
Calcification
of basal ganglia, 345
Calcium channel blockers
for amnesia, 864
for bipolar disorder, 149-ed
Caloric intake
increased, thyroid abnormalities in anorexia nervosa and, 48
Cancer therapy
melatonin and, 1-ed
Car exhaust
cacosmia and, 857
Carbamazepine
for bipolar disorder, 149-ed
clonidine test and, 893
kindling in bipolar disorders and, 70
for mixed states, 493
for negative symptom schizophrenia, 22
neuroactive steroids and, 775
sleep-EEG and, 893
Carbohydrate craving
in seasonal affective disorder, 284
Carpet
new, cacosmia and, 857
Catecholamines
in mixed affective states, 803
in schizophrenia, 203
Caudate nucleus
in bipolar affective disorder, 121
brain iron in Alzheimer's disease and, 480
CD3 lymphocytes
immunological function in schizophrenia and, 173
CD4 count
event-related potentials in HIV-1 infection and, 54
$CD4^+$ $2H4^+$ T cells
in schizophrenia, 27
$CD8^+$ $2H4^+$ T cells
in schizophrenia, 27
Cell-mediated immunity

cytokine production in major depression and, 42
prolyl endopeptidase and, 545
Center for Epidemiologic Studies Depression self-rating scale
low illumination and, 403
Central nervous system (CNS)
atrial natriuretic factor and, 272
cytokine production in major depression and, 42
neuroactive steroids and, 775
Cerebral cortex
dopamine receptor antagonist binding sites in fetal forebrain and, 562
in schizophrenia, 84
Cerebral ventricular size
stability of, in development of schizophrenia, 960
Cerebrospinal fluid (CSF)
in anorexia nervosa, 48
in affective disorders, 775
in obsessive-compulsive disorder, 143
in schizophrenia, 501
Cerebrum
euthyroidism and, 814
CH50 serum complement
immunological function in schizophrenia and, 173
Chaos
Alzheimer's disease and, 381
nonlinear dynamics and, 352
Chemicals
environmental, sensitization to early life stress and, 857
somatization disorder and, 82-ed
Childhood abuse
somatization disorder and, 81-ed
Childhood schizophrenia spectrum disorder
blink rate in, 228
Children
attention-deficit hyperactivity disorder in, 398
migrainous, platelet serotonin transporter in, 452
schizophrenia in, 228, 517, 525
Tourette's disorder in, 495
m-Chlorophenylpiperazine (*m*CPP)
adverse early experiences and, 221
behavioral response to, 426-corr
clozapine and, 909
Chlorpromazine
for schizophrenia, 135
Cholesterol
blood, 5-HIAA and, 957
lowering, violent deaths and, 575
Chronic fatigue syndrome (CFS)
somatization disorder and, 82-ed
Chronobiology
of schizophrenia, 151
Circadian rhythms
melatonin and, 1-ed
of MHPG in major depression, 830
in schizophrenia, 151
thyroid status, MAOI interaction and, 324
TSH in seasonal affective disorder and, 36
cis-flupenthixol
effect of on neuroblastoma cell line, 824
Clomipramine
cytokine production in major depression and, 42
Clonidine
carbamazepine and, 893
melatonin and, 139
Clopenthixol
QEEG and, 367
Clorgyline
serotonin transporter mRNA and, 287
thyroid state, light and, 324
Clozapine
*m*CPP and, 909
for schizophrenia, 278, 888
tardive dyskinesia and, 886
Clustered episodes
kindling in bipolar disorders and, 70
Cocaine
lisuride and, 843
serum prolactin and, 573
Cochran-Mantel-Haenzel test
accident proness correlated with handedness and, 499-corr
Cognitive components
event-related potentials in HIV-1 infection and, 54
Cognitive dysfunction
basal ganglia calcification and, 345
dorsolateral prefrontal lobe and, 235
in schizophrenia, 203, 517, 913
Cognitive enhancer
amnesia and, 864
Cognitive science
nonlinear dynamics and, 352
Combat veterans
REM sleep in PTSD and, 195
Community elderly
sleep and motor activity in, 73
Computed tomography (CT)
cerebral ventricular size stability in schizophrenia and, 960
Concanavalin A (Con A)
immunological function in schizophrenia and, 173
Concentration
impaired, fenfluramine challenge test and, 113
Continuous-performance task
in schizophrenia, 525
Conversation
blink rate in childhood schizophrenia and, 228
Convulsive threshold
ECT and, 427-corr
Corpus callosum
in first-episode schizophrenia, 913
Cortical blood flow
in obsessive-compulsive disorder, 426-corr
Corticotropin
in obsessive-compulsive disorder, 335
Corticotropin-releasing factor (CRF)
stimulation test, in obsessive-compulsive disorder, 143
Corticotropin-releasing hormone (CRH)
in major depression, 545

in somatization disorder, 82-ed
Cortisol
ACTH and, 309
buspirone and, 316
in depression, 309, 316
in mixed affective states, 803
in obsessive-compulsive disorder, 143
prolyl endopeptidase and, 545
in seasonal affective disorder, 36
TSH and, 36
Cosinor analysis
circadian rhythms in schizophrenia and, 151
CPRS-OC-5 Scale
in obsessive-compulsive disorder, 426-corr (response)
Craving
in psychostimulant withdrawal, 843
Cyclic adenosine monophosphate (cAMP)
lymphocyte β-adrenoceptors and, 920
Cycling frequency
kindling in bipolar disorders and, 70
Cytokines
in major depression, 42, 464
in schizophrenia, 464

Daylight
atypical depressive symptoms and, 403
Death wish
thalamic infarct and, 488
Delay-dependent speeding
of reaction time, in posttraumatic stress disorder, 500-corr
Delusions
in major depressive disorder, 464
in melancholic depression, 474
in schizophrenia, 3, 464
Dementia
basal ganglia calcification in, 345
EEG in, 870
event-related potentials in HIV-1 infection and, 54
monoamine oxidase B in, 772
platelet membrane fluidity and, 190
vitamin B_{12} in, 772
Depression
ACTH in, 309
akathisia and, 263
basal ganglia calcification in, 345
biogenic amines in, 803
brain monoamines in, 121
buspirone for, 316
cacosmia and, 857
cholesterol lowering in, 575
CSF protein in, 539
cytokines in, 42
D_2 receptors in, 128, 880
EEG sleep in, 781
fenfluramine challenge test in, 112
HPA function in, 803
interferon in, 464
low illumination and, 403
lymphocyte β-adrenoceptors in, 920
maintenance treatment for, 781
MHPG in, 830
migraine and, 452
nap after sleep deprivation and, 794
olfactory sensitivity in, 798
P300 component in, 474
panic attacks in multiple sclerosis and, 133
pregnenolone in, 775
prolactin in, 440
prolyl endopeptidase in, 545
psychostimulant withdrawal in, 843
serotonin in, 295, 457, 488
slowness of movement in, 253
suicide victims and, 457
thalamic infarct and, 488
total sleep deprivation for, 880
triiodothyronine in, 814
TSH in, 36
Depressive mania
bupropion for, 493
Design fluency
negative symptoms in schizophrenia and, 164
Desipramine
thyroid hormone concentrations and, 214
Desynchronized tapping
force control in schizophrenia and, 104
Detoxification
preventing heroin reabuse after, 935
Dexamethasone (DEX)
ACTH in depression and, 309
Dexamethasone suppression test (DST)
prolyl endopeptidase and, 545
Diazepam
use of by elderly, 73
Diazepam binding inhibitor (DBI)
in affective disorders, 775
Dichotic listening
in posttraumatic stress disorder, 500-corr
Diltiazem
for bipolar disorder, 149-ed
Dipeptidyl peptidase IV
prolyl endopeptidase and, 545
Diphenylbutylpiperidines
negative symptoms in schizophrenia and, 23
1,6-Diphenyl-1,3,5-hexatriene (DPH)
platelet membrane fluidity and, 190
Directional motor neglect
in posttraumatic stress disorder, 500-corr
Disdiadochokinesia
thalamic infarct and, 488
Dista Fellowship Award
information on, 79
Diurnal depressive mood disorders
serotonin in, 488
Dopamine
in bipolar affective disorder, 121
blink rate and, 228

blockade, sexual function in schizophrenic men and, 32
carbamazepine in schizophrenia and, 23
D_2 receptors, in depression, 128
hypothesis, of depression, 880
in posttraumatic stress disorder, 500-corr
psychostimulant withdrawal and, 843
receptor antagonist binding sites, in fetal forebrain, 562
receptors, in epileptic psychoses, 375
slowness of movement and, 253
in Tourette's disorder, 495
Dorsolateral prefrontal cortex
in schizophrenia, 235
Down's syndrome
adult, QEEG of premature aging in, 422
Drowsiness
fenfluramine challenge test and, 113
Drug overdose
serotonin receptors in suicide victims and, 457
Drug user risk group
HIV-1 infected, event related potentials in, 54
Dynorphin
in obsessive-compulsive disorder, 335
Dyscoordination
thalamic infarct and, 488
Dyskinesia
force control in schizophrenia and, 104
Dysphoria
in self-injurious borderline patients, 207
Dysphoric mania
bupropion for, 493
Dysregulation theory
MHPG in major depression and, 830
Dysthymic disorders
lymphocyte β-adrenoreceptors in, 920
Dystonia
basal ganglia calcification in, 345
neuroleptic-induced, overflow movements in, 491

Eating disorders
growth hormone-releasing factor in, 446
TRH in, 48
tryptophan depletion in bulimia and, 388
Educational achievement
low, in childhood onset schizophrenia, 517
Elderly
Alzheimer's disease in, 772
cacosmia in, 857
melatonin and, 1-ed
sleep and motor activity in, 73
Electric shocks
anticipation of, in panic disorder, 431
Electroconvulsive therapy (ECT)
mixed states and, 493
nifedipine and, 864
overflow movements and, 491
oxytocin release and, 963-corr, 964-corr (comment), 964-corr (response)
propofol and methohexital as anesthetic agents for, 179
seizure threshold and, 427-corr
Electroencephalogram (EEG)
in Alzheimer's disease, 381
carbamazepine and, 893
in dementia, 870
P300s in schizophrenia and, 96
sleep, depression and, 781
sleep, nap after sleep deprivation and, 794
in somatization disorder, 82-ed
Electromyography (EMG)
ballistic movements and, 253
Emotional abuse
somatization disorder and, 81-ed
Endocrine side effects
sexual function in schizophrenic men and, 32
Endogenous opioid system
in self-injurious borderline patients, 207
β-Endorphin
in major depression, 545
in obsessive-compulsive disorder, 335
Epidemiological survey
of polydipsia, 408
Epileptic psychoses
striatal dopamine receptor binding in, 375
Episode markers
in schizophrenia, 203
Erection
in schizophrenic men, 32
Euthymia
neuroactive steroids and, 775
TSH in seasonal affective disorder and, 36
Euthyroidism
depression and, 814
Evening
TSH response to TRH in major depression in, 926
Event-related potentials (ERPs)
cognitive, in HIV-1 infection, 54
in schizophrenia, 96, 850
Executive-attention measures
dorsolateral prefrontal lobe and, 235
Extrapyramidal nuclei
brain iron in Alzheimer's disease and, 480
Extrapyramidal symptoms
carbamazepine in schizophrenia and, 22
sexual function in schizophrenic men and, 32
Eye movement
in posttraumatic stress disorder, 500-corr
Eyeblink component
of acoustic startle reflex, in panic disorder, 431

Facial memory task
cerebral blood flow in schizophrenia and, 3
Fall
seasonal affective disorder and, 36, 284
Family history
of attention-deficit hyperactivity disorder in second-degree relatives, 398
of platelet membrane fluidity in Alzheimer's disease, 190

Fascicle coherence
EEG and, 870
Fatigue
melatonin and, 1-ed
in psychostimulant withdrawal, 843
seasonal affective disorder and, 284
Fear-potentiated startle
in panic disorder, 431
Fenfluramine
biobehavioral responses to, 112
Ferritin
brain iron in Alzheimer's disease and, 480
Fetus
dopamine receptor antagonist forebrain binding sites in, 562
Field dependent transverse relaxation rate increase (FDRI)
brain iron in Alzheimer's disease and, 480
Flash stimulation
in obsessive-compulsive disorder, 247
Flexion movement
in melancholia, 253
Fluency tests
negative symptoms in schizophrenia and, 164
Fluid volume
regulation of, atrial natriuretic peptide in, 272
Fluoxetine
nighttime plasma melatonin levels and, 139
thalamic infarct and, 488
Flupenthixol
effect of on neuroblastoma cell line, 824
Fluphenazine
effect of on neuroblastoma cell line, 824
Flurazepam
use of by elderly, 73
Food consumption
growth hormone-releasing factor effects on, 446
Food sensitivities
cacosmia and, 857
Food stressors
in somatization disorder, 82-ed
Foraging requirements
adverse early experiences and, 221
Force control
in schizophrenia, 104
Forebrain
fetal, dopamine receptor antagonist binding sites in, 562
Formal thought disorder
blink rate in childhood schizophrenia and, 228
Fractal dimension
Alzheimer's disease and, 381
nonlinear dynamics and, 352
Frontal cortex
in bipolar affective disorder, 121
serotonin receptors in suicide victims and, 457
Frontal lobe
brain iron in Alzheimer's disease and, 480
Frontal-parietal area
in schizophrenia, 501
Fuzziness
melatonin and, 1-ed

Ganglion cells
sympathetic, programmed cell death and, 946
Gaze disorders
in posttraumatic stress disorder, 500-corr
Gender
anesthetic agents for ECT and, 179
buspirone in depression and, 316
cacosmia and, 857
cholesterol lowering by statins and, 575
circadian rhythms in schizophrenia and, 151
corpus callosum size in first-episode schizophrenics and, 913
CSF protein in depression and, 539
cytokine production in major depression and, 42
deported sexual function and, 32
immunological function in schizophrenia and, 173
infantile autism and, 281
interferon responses in schizophrenia and MDD and, 464
obsessive-compulsive disorder and, 247
P300 in melancholic depression and, 474
panic attacks in multiple sclerosis and, 133
polydipsia with water intoxication and, 408
prolactin in adolescent major depressive disorder and, 440
somatization disorder and, 81-ed
Gene transcription
new, programmed cell death and, 946
Genes
in attention-deficit hyperactivity disorder, 398
in infantile autism, 281
Genome mismatch scanning
mental illness and, 757-ed
George N. Thompson Founders Award for Distinguished Service 1994
information on, 79
Gestation
dopamine receptor antagonist binding sites in fetal forebrain and, 562
Giddiness
melatonin and, 1-ed
Global increase
cerebral blood flow in schizophrenia and, 3
Globus pallidus
basal ganglia calcification in, 345
brain iron in Alzheimer's disease and, 480
Glutamate hypothesis
of schizophrenia, 84
α-Glycerophosphate dehydrogenase
euthyroidism and, 814
Goal weight
thyroid abnormalities in anorexia nervosa and, 48
Gold Medal Award 1994
guidelines for, 78
Gonadotrophins
melatonin and, 1-ed
Granulocytosis
lithium-induced, in bipolar affective disorder, 210

Grasp reflex
in affective psychoses, 217
Gray matter
temporal lobe, in schizophrenia, 501
Gray-white matter boundary
dopamine receptor antagonist binding sites in fetal forebrain and, 562
Growth factors
brain, in infantile autism, 281
Growth hormone (GH)
circadian rhythms of, in schizophrenia, 151
Growth hormone-releasing factor (GRF)
effects of on food consumption, 446
Growth rate
euthyroidism and, 814
Gyri
temporal lobe, in schizophrenia, 501

Hallucinations
basal ganglia calcification and, 345
cerebral blood flow in schizophrenia and, 3
interferon responses in schizophrenia and MDD and, 464
melancholic depression and, 474
thalamic infarct and, 488
Haloperidol
effect of on neuroblastoma cell line, 824
overflow movements and, 491
QEEG and, 367
Hamilton Anxiety Rating Scale
in obsessive-compulsive disorder, 143
Hamilton Depression Rating Scale
carbamazepine in schizophrenia and, 22
lymphocyte β-adrenoceptors and, 920
nap after sleep deprivation and, 794
in obsessive-compulsive disorder, 143
thalamic infarct and, 488
Handedness
accident proneness and, 499-corr
in obsessive-compulsive disorder, 247
Headache
melatonin and, 1-ed
Head injuries
handedness and, 499-corr
Health care costs
somatization disorder and, 81-ed
Heart rate
autonomic, clozapine and, 888
euthyroidism and, 814
Hebb's digit-sequences recall test
in schizophrenia, 164
Hematologic changes
lithium-induced, in bipolar affective disorder, 210
Hemispheric changes
cerebral blood flow in schizophrenia and, 3
Heroin
reabuse, naltrexone in preventing, 935
High resolution scanner
cerebral blood flow in schizophrenia and, 3
Himwich, Williamina Elizabeth Armstrong (in memoriam), 291
Hippocampus
glutamate receptors in, 85
norepinephrine in, 903
in schizophrenia, 164, 203, 501
Hoch, Paul, 901-ed
Homovanillic acid (HVA)
in bipolar affective disorder, 121
in depression, 128
in schizophrenia, 203
Hormones
clozapine and, 909
Hostility
cacosmia and, 857
cholesterol lowering and, 575
Human immunodeficiency virus (HIV) infection
cognitive event-related potentials in, 54
serum antibody in, 335
Humoral immunity
cytokine production in major depression and, 42
Huntington's disease
programmed cell death in, 946
5-Hydroxyindoleacetic acid (5-HIAA)
in bipolar affective disorder, 121
cholesterol and, 957
Hyperactivity
akathisia and, 263
Hyperprolactinemia
cocaine dependence and, 573
Hypersomnia
in psychostimulant withdrawal, 843
in seasonal affective disorder, 284
Hyperthyroidism
subclinical, depression and, 814
Hypnotic drugs
use of by elderly, 73
Hypocholesterolemic treatment
violent deaths and, 575
Hypothalamic-pituitary-adrenal (HPA) axis
cytokine production in major depression and, 42
mixed affective states and, 803
prolyl endopeptidase and, 545
Hypothalamic-pituitary-thyroid (HPT) axis
TSH in seasonal affective disorder and, 37
Hypothalamus
fenfluramine challenge test and, 113
melatonin and, 1-ed
Hypothyroidism
cacosmia and, 857
in depression, 814
light, MAOI interaction and, 324
in seasonal affective disorder, 36
Hysteria
somatization disorder and, 81-ed

IGF2 gene
in infantile autism, 281

Illumination
  low, atypical depressive symptoms and, 403
Illusions
  fenfluramine challenge test and, 112
Imipramine
  EEG sleep and, 781
  migraine and, 452
  serotonin transporter mRNA and, 287
Immune response
  cytokine production in major depression and, 42
  prolyl endopeptidase and, 545
  in schizophrenia, 27, 135, 173
Immunoglobulins
  in schizophrenia, 135, 173
Immunostimulation
  melatonin in, 1-ed
Impulsivity
  serotonin function and, 570
Infantile autism
  genetic factors in, 281
Inflammatory response
  prolyl endopeptidase and, 545
Information processing
  in obsessive-compulsive disorder, 247
  in schizophrenia, 525
INS gene
  in infantile autism, 281
Insomnia
  melatonin and, 1-ed
  thalamic infarct and, 488
Intelligence quotient (IQ)
  lower, in childhood onset schizophrenia, 517
Interferon (IFN)
  in schizophrenia and major depressive disorders, 464
Interleukin 1β (IL-1β)
  in major depression, 42
Interleukin 2 (IL-2)
  in major depression, 42
Interleukin 3 (IL-3)
  in major depression, 42
^{123}I-Iodobenzamide
  D_2 receptors in depression and, 128
  striatal dopamine receptor binding in epileptic psychoses and, 375
Ipsapirone
  buspirone in depression and, 316
Iron
  in Alzheimer's disease, 480
  in tardive dyskinesia, 16
Irritable bowel syndrome
  cacosmia and, 857
  somatization disorder and, 81-ed
Isoamyl acetate
  olfactory sensitivity to in major depressive disorder and obsessive-compulsive disorder, 798
Isoproterenol
  lymphocyte β-adrenoceptors and, 920
Israel
  heroin addicts in, 935

Jet lag
  melatonin and, 1-ed

Kainate
  glutamate receptors and, 85
Ketamine
  PCP-like abnormalities and, 84
Kidneys
  euthyroidism and, 814
Kindling
  in bipolar disorders, 70
  in somatization disorder, 82-ed

Latencies
  in obsessive-compulsive disorder, 247
  in panic disorder, 420
  P300s in schizophrenia and, 96
Lateral ventricles
  in schizophrenia, 3, 164, 501
Leap-frog feedback
  better administration and, 827-ed
Learned helplessness
  hippocampal norepinephrine and, 903
Left temporal lobe
  cerebral blood flow in schizophrenia and, 3
Left-ear advantage
  in posttraumatic stress disorder, 500-corr
Lethargy
  TSH in seasonal affective disorder and, 37
Leukocytes
  interferon responses in schizophrenia and MDD and, 464
Leukocytosis
  sulpiride dosage and, 963-corr
Light-dark cycle
  thyroid status, MAOI interaction and, 324
Light exposure
  atypical depressive symptoms and, 403
  bright, melatonin and, 1-ed
  for seasonal afective disorder, 284
Limbic system
  in somatization disorder, 82-ed
Lipid peroxidation
  platelet membrane fluidity in Alzheimer's disease and, 190
Lipopolysaccharide (LPS)
  interferon responses in schizophrenia and MDD and, 464
Lisuride
  in stimulant abusers, 843
Lithium
  for bipolar disorder, 70, 121, 149-ed, 210
  buspirone challenge test and, 553
  kindling and, 70
  for mixed states, 493
  thalamic infarct and, 488
Liver
  euthyroidism and, 814
Loss of interest

thalamic infarct and, 488
Lumbar puncture
CSF neuroactive steroids and, 775
Lupus anticoagulant antibodies
Tourette's disorder and, 495
Luteal phase
magnesium measures across menstrual cycle in PMS and, 557
Luteinizing hormone-releasing hormone (LHRH)
in major depression, 545
Lymphocytes
β-adrenergic responsivity and, 920
immunological function in schizophrenia and, 173

Magnesium
blood, premenstrual syndrome and, 557
Magnet reaction
in affective psychoses, 217
Magnetic resonance imaging (MRI)
basal ganglia iron in tardive dyskinesia and, 16
brain iron in Alzheimer's disease and, 480
corpus callosum size in first-episode schizophrenics and, 913
in schizophrenia, 235
tardive dyskinesia in AIDS and, 147-corr
temporal lobe structures in schizophrenia and, 501
thalamic infarct and, 488
Maintenance treatment
for depression, EEG sleep and, 781
Major depressive disorder
in adolescents, 440
anorexia nervosa and, 48
buspirone in, 316
CSF protein in, 539
cytokines in, 42
interferon in, 464
lymphocyte, β-adrenoceptors and, 920
MHPG in, 830
nap after sleep deprivation and, 794
olfactory sensitivity in, 798
in posttraumatic stress disorder, 195
prolactin in, 440
prolyl endopeptidase in, 545
serotonin receptor function in, 295
somatization disorder and, 81-ed
thalamic infarct and, 488
TSH response to TRH in, 926
Malondialdehyde
plasma, in Alzheimer's disease, 190
Mania
biogenic amines in, 803
bupropion for, 493
buspirone-induced prolactin release in, 553
calcium antagonists for, 149
CSF protein in, 539
HPA function in, 803
kindling in, 70
somatization disorder and, 81-ed
transient release reflexes in, 217
Manic-depressive illness
bupropion and, 493
Manic mood syndrome
transient release reflexes in, 217
Masturbation
in schizophrenic men, 32
Mayeux-modified minimental state exam 52/57
thalamic infarct and, 488
Medial-frontal-striatal activation system
in posttraumatic stress disorder, 500-corr
Medial temporal lobe
in schizophrenia, 203
Melancholia
buspirone in, 316
P300 component in, 474
prolyl endopeptidase and, 545
slowness of movement in, 253
Melatonin
agonists and, 1-ed
circadian rhythms of, in schizophrenia, 151
nighttime plasma levels, fluoxetine and, 139
Memory
cerebral blood flow in schizophrenia and, 3
ECT and, 179, 864
as episode marker in schizophrenia, 203
nifedipine and, 864
Menstrual cycle
magnesium measures across, in PMS, 557
MESORs
circadian rhythms in schizophrenia and, 151
Messenger RNA (mRNA)
serotonin transporter, 287
Metabolism
brain iron in Alzheimer's disease and, 480
euthyroidism and, 814
Metergoline
in obsessive-compulsive disorder, 426-corr
Methohexital
as anesthetic agent for ECT, 179
3-Methoxy-4-hydroxyphenylglycol (MHPG)
in bipolar affective disorder, 121
in major depression, 830
in mixed affective states, 803
Midtemporal region
cerebral blood flow in schizophrenia and, 3
Migraine headache
cacosmia and, 857
platelet serotonin transporter in, 452
Mind-body interactions
somatization disorder and, 82-ed
Mitochondrial mutation
in mental illness, 759-ed
Mitogens
immunological function in schizophrenia and, 173
Mixed affective states
biogenic amines and HPA function in, 803
Mixed mania

bupropion for, 493
MK-801
PCP-like abnormalities and, 84
MMN
event-related potentials in HIV-1 infection and, 54
Molecular biology
programmed cell death and, 946
Molecular genetics
of mental illness, 757-ed
Molestation
somatization disorder and, 81-ed
Monoamine oxidase B (MAO-B)
in dementia, 772
Monoamine oxidase inhibitor (MAOI)
thyroid state, light and, 324
Monoamines
brain, in bipolar affective disorder, 121
Mononuclear blood cells (MBCs)
magnesium measures in PMS and, 557
Mononuclear leukocytes (MNLs)
β-adrenergic responsivity and, 920
Montgomery-Åsberg Depression Rating Scale
anesthetic agents for ECT and, 179
Mood
lisuride and, 843
low illumination and, 403
magnesium measures across menstrual cycle in PMS and, 557
thalamic infarct and, 488
tryptophan depletion in bulimia and, 388
Mood disorders
basal ganglia calcification in, 345
brain monoamines in, 121
CSF neuroactive steroids in, 775
dopamine in, 128
multiple sclerosis and, 133
serotonin in, 488
Mood elevation
fenfluramine challenge test and, 112
Morning
TSH in seasonal affective disorder and, 36
TSH response to TRH in major depression in, 926
Morphine
somatization disorder and, 82-ed
Motor activity
bedtime medication use by elderly and, 73
Motor impersistence
left-sided, thalamic infarct and, 488
Motor incoordination
force control in schizophrenia and, 104
Motor readiness
in posttraumatic stress disorder, 500-corr
Movement
force control in schizophrenia and, 104
slowness of, in melancholia, 253
Movement sequences
difficulty following, force control in schizophrenia and, 104
Multiple sclerosis (MS)
panic attacks in, 133
serum antibody in, 335
Muscle force
in neuroleptic-naive schizophrenics, 104
Myoclonus
basal ganglia calcification and, 345
thalamic infarct associated with, 488

N1 amplitude
event-related potentials in HIV-1 infection and, 54
in obsessive-compulsive disorder, 247
in schizophrenia, 525
Naloxone
in self-injurious borderline patients, 207
Naltrexone
in preventing heroin reabuse, 935
Nap
after sleep deprivation, 794
Naphthalene derivative
melatonin and, 2-ed
Natural killer (NK) cells
immunological function in schizophrenia and, 173
Nausea
melatonin and, 1-ed
Negative symptoms
in schizophrenia, 22, 164, 464, 517
Neural networks
as nonlinear dynamical systems, 352
Neuroblastoma cell line
inhibitory effect of psychoactive drugs on, 824
Neurodevelopmental disorders
programmed cell death in, 946
Neuroendocrine responses
clozapine and, 909
Neuroimaging
cerebral blood flow in schizophrenia and, 3
Neuroleptics
akathisia and, 263
basal ganglia iron and, 16
dopamine receptor antagonist binding sites in fetal forebrain and, 562
dystonia and, 491
force control in schizophrenia and, 104
kindling in bipolar disorders and, 71
natural autoantibodies and, 135
overflow movements and, 491
QEEG and, 367
resumption of in drug-free chronic schizophrenics, 429-corr
schizophrenic children and, 228
Neurologic soft signs
force control in schizophrenia and, 104
Neuronal sprouting
overflow movements and, 491
Neurons
programmed cell death and, 946
Neuropsychological status
in schizophrenia, 517
Newcastle disease virus (NDV)

interferon responses in schizophrenia and MDD and, 464
Nifedipine
ECT and, 864
Nightmares
in posttraumatic stress disorder, 195
Nighttime
plasma melatonin levels, fluoxetine and, 139
TSH surge, in seasonal affective disorder, 36
NIMH-OC Scale
in obsessive-compulsive disorder, 427-corr (response)
Nimodipine
for bipolar disorder, 149-ed
N-methyl-D aspartate (NMDA)
receptor, in schizophrenia, 84
Nonlinear dynamical psychiatry
Alzheimer's disease and, 381
development of, 352
Noradrenaline
mood disorders and, 128
Noradrenergic system
adverse early experiences and, 221
Norepinephrine
in bipolar affective disorder, 121
MHPG in major depression and, 830
mild restress and, 903
in mixed affective states, 803
Nutritional status
thyroid abnormalities in anorexia nervosa and, 48

Obsessive-compulsive disorder (OCD)
autoimmunity in, 335
corticotropin-releasing factor stimulation test in, 143
evoked potentials in, 247
*m*CPP in, 426-corr
olfactory sensitivity in, 798
serum antibody in, 335
Occipital cortex
in bipolar affective disorder, 121
Occipital EEG
in Alzheimer's disease, 381
Oddball paradigm
P300 in melancholic depression and, 474
Olfactory sensitivity
in major depressive disorder and obessive-compulsive disorder, 798
Ontogeny
dopamine receptor antagonist binding sites in fetal forebrain and, 562
Opiate antagonist
in self-injurious borderline patients, 207
Opioid peptides
interferon responses in schizophrenia and MDD and, 464
somatization disorder and, 82-ed
Orbital frontal area
in schizophrenia, 235
Org 3770
melatonin and, 139
Organ weights
euthyroidism and, 814
Ovarian cysts
somatization disorder and, 81-ed
Overflow movements
in prediction of neuroleptic-induced dystonia, 491
Oxaprotiline
melatonin and, 139
Oxytocin
release, ECT efficacy and, 963-corr, 964-corr (comment), 964-corr (response)

P1 amplitude
event-related potentials in HIV-1 infection and, 54
in schizophrenia, 525
P2 amplitude
in obsessive-compulsive disorder, 247
P3 amplitude
event-related potentials in HIV-1 infection and, 54
in schizophrenia, 525
P300 amplitude
in melancholic depression, 474
in schizophrenia, 96, 850
Pain perception
in self-injurious borderline patients, 207
Paint
cacosmia and, 857
Palmomental reflex
in affective psychoses, 217
Panic attacks
adverse early experiences and, 221
in multiple sclerosis, 133
Panic disorder
fenfluramine challenge test and, 113
social phobia and, 420
somatization disorder and, 81-ed
startle in, 431
Paranoia
basal ganglia calcification and, 345
Parenteral drug users
HIV-1 infected, event related potentials in, 54
Parietal cortex
in bipolar affective disorder, 121
Parietal electrode
P300s in schizophrenia and, 96, 850
Parietal negative component
in schizophrenia, 525
Parkinson's disease
slowness of movement in, 253
somatization disorder and, 81-ed
Pathological affect
thalamic infarct and, 488
Peptidases
in major depression, 545
Perceptual distortions
basal ganglia calcification in, 345
Perfume
cacosmia and, 857
Periictal schizophreniform psychosis

striatal dopamine receptor binding in, 375
Peripheral blood lymphocytes (PBLs)
in schizophrenia, 27
Peripheral blood mononuclear cells (PBMCs)
cytokine production by, in depression, 42
Peripheral nervous system (PNS)
cytokine production in major depression and, 42
Personality disorders
fenfluramine in, 112
serotonin receptor function and, 295
Pesticides
cacosmia and, 857
somatization disorder and, 82-ed
Pharmaceutical industry
calcium antagonists and, 149-ed
Phase shifting
melatonin and, 1-ed
Phasic event generation
REM sleep in PTSD and, 195
Phencyclidine (PCP)
glutamate receptors and, 84
3-(*p*-Phenyl-1,3,5-hexatrienyl)phenyl-propionic acid (DPH-PA)
platelet membrane fluidity and, 190
Phobia
social, 420
Phobic disorder
somatization disorder and, 81-ed
Phorbol myristate acetate (PMA)
interferon responses in schizophrenia and MDD and, 464
Phototherapy
melatonin and, 1-ed
for seasonal afective disorder, 284
Phytohemagglutinin (PHA)
in major depressive disorder, 464
in schizophrenia, 173, 464
Pimozide
negative symptoms in schizophrenia and, 23
Pineal gland
melatonin output from, 139
Pituitary gland
anterior, fenfluramine challenge test and, 113
prolactin, in major depressive disorder, 440
in schizophrenia, 151
Platelet membrane fluidity
in Alzheimer's disease, 190
Platelets
aggregation of, serotonin and, 295
in dementia, 772
lithium-induced changes in, in bipolar affective disorder, 210
migraine and, 452
Pokeweed mitogen
immunological function in schizophrenia and, 173
Polycystic ovary disease
somatization disorder and, 81-ed
Polydipsia
epidemiological review of, 408
Polysomnography
of social phobia, 420
Positive symptoms
force control in schizophrenia and, 104
Posttraumatic stress disorder (PTSD)
mild stress and, 903
neurobiology of, 500-corr
REM sleep in, 195
Postural tremor
basal ganglia calcification and, 345
Prefrontal lobe
in schizophrenia, 235
Pregnenolone
affective disorders and, 775
Premature aging
in adult Down's syndrome, 422
Premenstrual syndrome (PMS)
magnesium measures across menstrual cycle in, 557
Premorbid function
in schizophrenia, 517
Present State Examination
kindling in bipolar disorders and, 70
Primates
adult, adverse early experiences in, 221
Prince Henry Hospital Akathisia Rating Scale
new version of, 263
Probenecid technique
homovanillic acid in depression and, 128
Processing negativity
in schizophrenia, 525
Prodynorphin 209-240
serum antibody for, 335
Progesterone
affective disorders and, 775
Programmed cell death
in neuropsychiatric disorders, 946
Prolactin
adolescent major depressive disorder and, 440
buspirone and, 316, 553
circadian rhythms of, in schizophrenia, 151
clozapine and, 909
cocaine dependence and, 573
fenfluramine challenge test and, 112
melatonin and, 1-ed
sexual function in schizophrenic men and, 32
Prolyl endopeptidase
serum, in major depression, 545
Propofol
as anesthetic agent for ECT, 179
Protein
CSF, in depression, 539
Proteinases
in major depression, 545
Protein kinases
Ca-activated, carbamazepine in schizophrenia and, 23
Psychiatric Symptom Assessment Scale
neuroleptic remedication in drug-free chronic schizophrenics and, 429-corr (response)

Psychiatry
  new dynamics and, 352
Psychogenic disorders
  somatization disorder and, 81-ed
Psychoimmunology
  prolyl endopeptidase and, 545
Psychomotor retardation
  slowness of movement and, 253
  TSH in seasonal affective disorder and, 37
Psychosis
  AIDS and, 147-corr
  basal ganglia calcification in, 345
  fenfluramine challenge test and, 112
  immunological function in schizophrenia and, 173
  melancholic depression and, 474
  neuroleptic remedication in, 429-corr
  prolactin in adolescent major depressive disorder and, 440
  striatal dopamine receptor binding in, 375
  T-cell subsets in, 27
  transient release reflexes in, 217
Psychosocial stressors
  kindling in bipolar disorders and, 70
Pursuit tracking
  disturbed, force control in schizophrenia and, 104
Putamen
  brain iron in Alzheimer's disease and, 480

Quantitative electroencephalogram (QEEG)
  alpha1 chnges, in schizophrenia, 367
  of premature aging in adult Down's syndrome, 422

R_2 transverse relaxation rate
  brain iron in Alzheimer's disease and, 480
Race
  polydipsia with water intoxication and, 408
Radiolabeled receptor assay
  of glycine binding sites in schizophrenia, 84
Rapid cycling
  kindling in bipolar disorders and, 70
Rapid eye movement (REM) sleep
  carbamazepine and, 893
  imipramine and, 781
  lisuride and, 843
  in panic disorder, 420
  in posttraumatic stress disorder, 195
Reaction time
  in posttraumatic stress disorder, 500-corr
Receptor autoradiography
  dopamine receptor antagonist binding sites in fetal forebrain and, 562
Red blood cells (RBCs)
  lithium-induced changes in, in bipolar affective disorder, 210
  magnesium measures across menstrual cycle in PMS and, 557
Regional activation
  cerebral blood flow in schizophrenia and, 3
Representational difference analysis
  mental illness and, 757-ed
Research Diagnostic Criteria
  kindling in bipolar disorders and, 70
Restress
  mild, hippocampal norepinephrine and, 903
Right cerebral hemisphere
  in posttraumatic stress disorder, 500-corr
RT count
  event-related potentials in HIV-1 infection and, 54

Scale for the Assessment of Negative Symptoms
  in schizophrenia, 22, 164
[^{3}H]-SCH23390
  binding sites, in fetal forebrain, 562
Schedule for Affective Disorders
  kindling in bipolar disorders and, 70
  in obsessive-compulsive disorder, 143
Schizophrenia
  akathisia and, 263
  alogia in, 164
  basal ganglia calcification in, 345
  basal ganglia iron in, 16
  carbamazepine in, 22
  cerebral blood flow in, 3
  cerebral ventricular size stability in, 960
  chronobiology of, 151
  clozapine for, 278, 888
  continuous-performance task in, 525
  corpus callosum in, 913
  CSF protein in, 539
  deported sexual function in, 32
  episode markers in, 203
  event-related potentials in, 525
  flat affect in, 164
  force control in, 104
  glycine-binding sites in, 84
  heart rate variability in, 888
  homovanillic acid in, 203
  immunological function in, 173
  interferon in, 464
  memory in, 203
  natural autoantibodies in, 135
  neuroleptic remedication in, 429-corr
  neuropsychological status in, 517
  nonlinear dynamics in, 352
  P300 in, 96, 850
  parietal negative component in, 525
  polydipsia with water intoxication in, 408
  prefrontal MRI in, 235
  premorbid function in, 517
  programmed cell death in, 946
  QEEG in, 367
  serum antibody in, 335
  T-cell subsets in, 27
  temporal lobe structures in, 501
  transient release reflexes in, 217
  ventricle-brain ratio in, 517
  ventricular enlargement in, 517

Schizophreniform disorder
cerebral ventricular size stability in, 960
Schizotypal personality disorder
blink rate in, 228
Seasonal affective disorder (SAD)
low illumination and, 403
prevention of, 284
TSH secretion in, 36
Second-degree relatives
attention-deficit hyperactivity disorder in, 398
Seizure disorders
somatization disorder and, 82-ed
Seizure duration
in ECT, effect of anesthetic agents on, 179
Seizure threshold
ECT and, 427-corr
Self-injurious behavior
in borderline personality disorder, 207
Sensory processing
low-level, in obsessive-compulsive disorder, 247
September
light exposure at end of, 284
D-Serine
glycine binding sites in schizophrenia and, 85
Serine proteinase
in major depression, 545
Serotonergic system
adverse early experiences and, 221
Serotonergic transmission
increased, fenfluramine challenge test and, 112
Serotonin (5-HT)
aggression and, 570
agonist, *m*CPP and, 909
in bipolar affective disorder, 121
in bulimia, 388
buspirone and, 316, 553
cholesterol and, 575, 957
circadian rhythms of, 151
in depression, 316
melatonin and, 139
in mood disorders, 128
in obsessive-compulsive disorder, 426-corr
platelet receptor binding indices and, 295
prolactin release in mania and, 553
receptors, in suicide victims, 457
in schizophrenia, 151
thalamic infarct and, 488
transporter, in migrainous children, 452
transporter mRNA, antidepressants and, 287
tryptophan depletion and, 388
Sex effect
CSF protein in depression and, 539
Sexual abuse
somatization disorder and, 81-ed
Sexual function
in schizophrenic men, 32
Sexual harrassment
early account of, 293-ed, 294-ed (response)
Shagass, Charles (in memoriam), 365
Shift work
melatonin and, 1-ed
Shocks
anticipation of, in panic disorder, 431
Shuttlebox avoidance task
learned helplessness and, 903
Shyness
cacosmia and, 857
Signal-to-noise ratio
P300s in schizophrenia and, 96
Simpson and Angus Scale
carbamazepine in schizophrenia and, 22
Single photon emission computed tomography (SPECT)
of D_2 receptors in depression, 128
striatal dopamine receptor binding in epileptic psychoses and, 375
total sleep deprivation and, 880
Sinusitis
cacosmia and, 857
SK-N-SH cells
inhibitory effect of psychoactive drugs on, 824
Sleep
bedtime medication use by elderly and, 73
deprivation, SPECT and, 880
EEG, carbamazepine and, 893
EEG, depression and, 781
EEG, nap after sleep deprivation and, 794
imipramine and, 781
lisuride and, 843
phase shift, melatonin and, 1-ed
in posttraumatic stress disorder, 195
in seasonal affective disorder, 36, 284
in social phobia, 420
TSH and, 36
Smoking
polydipsia with water intoxication and, 408
Social function
premorbid, in schizophrenia, 517
Social interactions
loss of, seasonal affective disorder and, 284
Social phobia
sleep architecture of, 420
Sodium
serum, in water intoxication, 408
Sodium homeostasis
atrial natriuretic peptide in, 272
Soft neurological signs
overflow movements and, 491
Solvents
somatization disorder and, 82-ed
Somatization disorder
lack of biological research on, 81-ed
Somatostatin-14
serum antibody for, 335
Spatial memory task
ECT and nifedipine effects on, 864
Speech

blink rate in childhood schizophrenia and, 228
Spleen
euthyroidism and, 814
Spring
seasonal affective disorder and, 36, 284
Squeeze movement
in melancholia, 253
Startle
in panic disorder, 431
State markers
for dementia, 870
Statins
cholesterol lowering by, 575
Steroids
CSF, in affective disorders, 775
Stimulant abuse
lisuride effect on mood and sleep in, 843
Stress
cacosmia and, 857
inescapable, hippocampal norepinephrine and, 903
kindling in bipolar disorders and, 70
Striatum
dopamine receptor binding in epileptic psychoses and, 375
psychoactive drugs and, 824
Strychnine-insensitive glycine binding site
in schizophrenia, 84
Suicidality
bipolar affective disorder and, 121
serotonin receptor function and, 295
Suicide victims
brain monoamines in, 121
serotonin receptors in, 457
Sulci
temporal lobe, in schizophrenia, 501
Sulpiride
therapeutic dosage, leukocytosis and, 963-corr
Summer
seasonal affective disorder and, 36, 284
Suprachiasmatic nucleus
melatonin and, 1-ed

T_2 relaxation time
brain iron in Alzheimer's disease and, 480
Tailshock stress
inescapable, hippocampal norepinephrine and, 903
Tardive dyskinesia
in AIDS, 147-corr
basal ganglia iron in, 16
clozapine and, 886
force control in schizophrenia and, 105
T-cells
subsets of, in acute psychotic schizophrenics, 27
Temporal cortex
in bipolar affective disorder, 121
Temporal lobe
in schizophrenia, 235, 501
Temporal lobe-like symptoms
basal ganglia calcification and, 345
Temporolimbic system
negative symptoms in schizophrenia and, 164
Testes
euthyroidism and, 814
Thalamus
in bipolar affective disorder, 121
infarct, serotinin and, 488
N-[1-(2-Thienyl)cyclohexyl]piperidine
PCP-like abnormalities and, 84
Thiopental
as anesthetic agent for ECT, 179
Thioridazine
sexual function in schizophrenic men and, 32
Third cerebral ventricle
in schizophrenia, 501
Thought disorders
interferon responses in schizophrenia and MDD and, 464
posttraumatic stress disorder and, 500-corr
Threat conditions
startle stimuli delivered in, in panic disorder, 431
Thymocytes
programmed cell death and, 946
Thyroid hormones
depression and, 814
TSH response to TRH in major depression and, 926
Thyroid-releasing hormone (TRH)
in anorexia nervosa, 48
in major depression, 545, 926
in seasonal affective disorder, 36
Thyroid status
light, MAOI interaction and, 324
Thyroid-stimulating hormone (TSH)
circadian rhythms of, in schizophrenia, 151
in major depression, 926
in seasonal affective disorder, 36
suppression of, 814
Thyrotoxicosis
depression and, 814
Thyroxine (T_4)
despipramine and, 214
suppression of, 814
TSH response to TRH in major depression and, 926
Time-dependent sensitization model
for cacosmia, 857
Topographical assymetries
in schizophrenia, P300 and, 850
Torsion dystonia
overflow movements and, 491
Total sleep deprivation (TSD)
SPECT and, 880
Tourette's disorder
antiphospholipid syndrome and, 495
Trait markers
for dementia, 870
trans-flupenthixol
effect of on neuroblastoma cell line, 824
Transient release reflexes
in affective psychoses, 217

Trauma-related memories
in posttraumatic stress disorder, 500-corr
Tremor
basal ganglia calcification and, 345
thalamic infarct and, 488
Tricyclic antidepressants
cytokine production in major depression and, 42
EEG sleep and, 781
serotonin receptors in suicide victims and, 457
serotonin transporter mRNA and, 287
triiodothyronine and, 814
Triiodothyronine (T_3)
depression and, 814
desipramine and, 214
thalamic infarct and, 488
TSH response to TRH in major depression and, 926
1-(4-Trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH)
platelet membrane fluidity and, 190
Trophic support
programmed cell death and, 946
Tryptophan
circadian rhythms of, in schizophrenia, 151
depletion, in bulimia, 388
melatonin and, 139
plasma, in aggressive patients, 570
Two-color flow cytometric analysis
of T-cell subsets in schizophrenia, 27
Two-tone auditory oddball event-related potential paradigm
P300s in schizophrenia and, 96

Underweight
thyroid abnormalities in anorexia nervosa and, 48
Unipolar depression
CSF protein in, 539
D_2 receptors in, 128
MHPG in, 830
triiodothyronine in, 814

Valproate
for bipolar disorder, 149-ed
for mixed states, 493
Valproic acid
kindling in bipolar disorders and, 70
Vasopressin
negative symptoms in schizophrenia and, 23
Ventricle-brain ratio
in schizophrenia, 517
Ventricular dilation
psychoactive drugs and, 824
Ventricular enlargement
in schizophrenia, 517
Verapamil
for bipolar disorder, 149-ed
Veratridine
glutamate receptors and, 85
Verbal memory task
cerebral blood flow in schizophrenia and, 3
in posttraumatic stress disorder, 500-corr
Verbal recall
blink rate in childhood schizophrenia and, 228
Viruses
interferon responses in schizophrenia and MDD and, 464
Visual coherence
EEG and, 870
Visual discrimination
in schizophrenia, 525
Visual evoked potentials
in obsessive-compulsive disorder, 247
Vitamin B_{12}
in dementia, 772
Voluntary motor disturbances
force control in schizophrenia and, 104

Water intoxication
polydipsia and, 408
Water regulation
atrial natriuretic peptide in, 272
Weight gain
in seasonal affective disorder, 36, 48, 284
Wheel-running
thyroid, light, MAOI interaction and, 324
White blood cells (WBCs)
lithium-induced changes in, in bipolar affective disorder, 210
White matter
brain iron in Alzheimer's disease and, 480
Whole blood culture
interferon responses in schizophrenia and MDD and, 464
Wilcoxon Two-Sample Test
neuroleptic remedication in drug-free chronic schizophrenics and, 429-corr (response)
Winter
seasonal affective disorder and, 36, 284
Withdrawal
interferon responses in schizophrenia and MDD and, 464
Word-finding
thalamic infarct and, 488
Word fluency
negative symptoms in schizophrenia and, 164
Worthlessness
feelings of, thalamic infarct and, 488

Xenon ^{133} Xenon clearance technique
in obsessive-compulsive disorder, 426-corr
in schizophrenia, 3

[^{3}H]-YM09151-2
binding sites, in fetal forebrain, 562
Yohimbine
adverse early experiences and, 221

Ziskind-Somerfield Research Award 1994
guidelines and instructions for, 77